We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed with EUA application to the FDA in...
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...
Β Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation Β TORONTO, February 15, 2022 -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 701 subjects dosed to date Initiating enrollment activities in Turkey as part of its...
Β Revive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsΒ IRB approval to initiate Phase 2 study for methamphetamine abuse disordersΒ Advancing psilocybin oral thin film...
Β Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19Β Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...
Β Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantΒ TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.00025 | -4.16666666667 | 0.006 | 0.0067 | 0.005 | 389611 | 0.00609381 | CS |
4 | -0.00025 | -4.16666666667 | 0.006 | 0.00778 | 0.005 | 435038 | 0.00624987 | CS |
12 | -0.00035 | -5.73770491803 | 0.0061 | 0.012 | 0.005 | 505592 | 0.00695676 | CS |
26 | -0.00625 | -52.0833333333 | 0.012 | 0.0135 | 0.005 | 381433 | 0.00741088 | CS |
52 | -0.01825 | -76.0416666667 | 0.024 | 0.036 | 0.005 | 356949 | 0.01324357 | CS |
156 | -0.24425 | -97.7 | 0.25 | 0.39 | 0.005 | 437328 | 0.10673653 | CS |
260 | -0.03525 | -85.9756097561 | 0.041 | 0.72 | 0.005 | 1068783 | 0.27621308 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions